David Reese (Amgen)
January 28, 2021 02:33 PM ESTUpdated January 30, 04:28 AM
R&D

Am­gen show­cas­es its last big round of promis­ing KRAS G12C da­ta for so­tora­sib. Next up: A like­ly mar­ket­ing cam­paign for a break­through ther­a­py

John Carroll

Editor & Founder

Am­gen is show­ing off the last, break­through round of da­ta it has from the piv­otal study for its KRAS G12C drug so­tora­sib in non-small cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times